<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111462</url>
  </required_header>
  <id_info>
    <org_study_id>20010102</org_study_id>
    <nct_id>NCT00111462</nct_id>
  </id_info>
  <brief_title>Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy</brief_title>
  <official_title>A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of darbepoetin alfa administered in a
      weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid
      malignancies receiving multicycle chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving a hemoglobin concentration greater than or equal to 12.0 g/dL or a greater than or equal to 2.0-g/dL increase in hemoglobin concentration compared to baseline</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to and percentage of subjects with a hemoglobin response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and percentage of subjects with hemoglobin correction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration and change in hemoglobin concentration from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first RBC transfusion and percentage of subjects receiving a RBC transfusion</measure>
  </secondary_outcome>
  <condition>Anemia</condition>
  <condition>Non-Myeloid Malignancies</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Planned chemotherapy treatment - Anemia (hemoglobin concentration
        less than or equal to 11.0 g/dL) - Adequate renal and liver function - Eastern Cooperative
        Oncology Group (ECOG) 0 to 2 - Subjects must provide written informed consent Exclusion
        Criteria: - Known history of seizure disorder - Known primary hematologic disorder causing
        anemia other than non-myeloid malignancies - Unstable/uncontrolled cardiac condition -
        Clinically significant inflammatory disease - Known positive test for HIV infection -
        Transfusion within 4 weeks of randomization - Neutralizing antibodies to any erythropoietic
        agent - Treatment with erythropoietic therapy within 4 weeks before randomization -
        Received any investigational drug or device within 30 days before randomization - Pregnant
        or breast feeding - Not using adequate contraceptive precautions - Previously randomized
        into this study - Known hypersensitivity to any products to be administered - Concerns for
        subject's compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb 15;100(4):859-68.</citation>
    <PMID>14770445</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2005</study_first_submitted>
  <study_first_submitted_qc>May 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2005</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-myeloid malignancy</keyword>
  <keyword>chemotherapy-induced anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

